Orismilast
Orismilast (LEO-32731) is an orally active and selective PDE4 inhibitor used for the research of inflammatory diseases. Orismilast demonstrates potent inhibition of PDE4B and PDE4D subtype splice variants[1][2].
Product Specifications
CAS Number
1353546-86-7
Product Name Alternative
LEO-32731
UNSPSC
12352005
Target
Phosphodiesterase (PDE)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/orismilast.html
Purity
99.88
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=S1(CCC2(OC3=C(C=CC(C(CC4=C(C=[N+](C=C4Cl)[O-])Cl)=O)=C3O2)OC(F)F)CC1)=O
Molecular Formula
C19H15Cl2F2NO7S
Molecular Weight
510.29
References & Citations
[1]Nielsen, et al.Preparation of benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors.WO2011160632A1.|[2]Jonathan I Silverberg, et al. Pharmacology of orismilast, a potent and selective PDE4 inhibitor. J Eur Acad Dermatol Venereol. 2023 Apr;37 (4) :721-729.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
PDE4
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LC422546 20 µg
Glyt1 (SLC6A9) (NM_001024845) Human Over-expression Lysate
Sign In for Pricing
View Details 
